⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5502103 | 0.71 | — | — | |
| SCHEMBL10458342 | 0.69 | — | — | |
| SCHEMBL9463592 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL28462716 | 0.67 | — | — | |
| SCHEMBL1133418 | 0.65 | — | — | |
| SCHEMBL9579841 | 0.64 | — | — | |
| SCHEMBL186450 | 0.60 | — | — | |
| SCHEMBL19821999 | 0.60 | — | — | |
| SCHEMBL6238591 | 0.59 | — | — | |
| SCHEMBL25910 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 437 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3931327-A1 | OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA | Phoenicis Therapeutics, Inc. (US) | 2022-01-05 | — | — | EP | claimed |
| US-11033571-B2 | Pharmaceutical composition for preventing or treating hepatitis B | AM SCIENCES INC (KR) | 2021-06-15 | — | — | US | claimed |
| US-10889817-B2 | Oligonucleotide therapy for Leber Congenital Amaurosis | PROQR THERAPEUTICS II B.V. (NL) | 2021-01-12 | — | — | US | claimed |
| US-20200063134-A1 | OLIGONUCLEOTIDE THERAPY FOR LEBER CONGENITAL AMAUROSIS | LABORATOIRES THEA (FR) | 2020-02-27 | — | — | US | claimed |
| US-20190343864-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEPATITIS B | AM SCIENCES INC (KR) | 2019-11-14 | — | — | US | claimed |
| EP-3556402-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEPATITIS B | AM Sciences Inc (KR) | 2019-10-23 | — | — | EP | claimed |
| US-10421963-B2 | Oligonucleotide therapy for leber congenital amaurosis | PROQR THERAPEUTICS II B.V. (NL) | 2019-09-24 | — | — | US | claimed |
| US-20190040399-A1 | CRISPR-CAS COMPONENT SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION | BROAD INST INC (US) | 2019-02-07 | — | — | US | claimed |
| US-8710023-B2 | Antisense modulation of C-reactive protein expression | ISIS PHARMACEUTICALS, INC. (US) | 2014-04-29 | — | — | US | claimed |
| US-20140080894-A1 | ENHANCED BIODISTRIBUTION OF OLIGOMERS | GROOVE BIOPHARMA CORPORATION | 2014-03-20 | — | — | US | claimed |
| US-20090275133-A1 | ANTISENSE MODULATION OF C-REACTIVE PROTEIN EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | claimed |
| EP-1937312-A4 | CHIMERIC OLIGOMERIC COMPOUNDS FOR MODULATION OF SPLICING | ISIS PHARMACEUTICALS INC (US) | 2009-01-07 | — | — | EP | claimed |
| EP-1937312-A2 | CHIMERIC OLIGOMERIC COMPOUNDS FOR MODULATION OF SPLICING | Isis Pharmaceuticals, Inc. (US) | 2008-07-02 | — | — | EP | claimed |
| WO-2007028065-A2 | CHIMERIC OLIGOMERIC COMPOUNDS FOR MODULATION OF SPLICING | ISIS PHARMACEUTICALS, INC. (US) | 2007-03-08 | — | — | WO | claimed |
| US-20060024727-A1 | Antisense modulation of C-reactive protein expression | ISIS PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | claimed |
| JP-2004509604-A | — | — | 2004-04-02 | — | — | JP | claimed |
| US-6653458-B1 | Phosphodiester or phosphorothioate internucleotide linkages at 2',5' positions; substituents at 3'; nuclease resistance and increased binding affinity; use as antisense agents | ISIS PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | claimed |
| EP-1263765-A1 | ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING | ISIS PHARMACEUTICALS, INC. (US) | 2002-12-11 | — | — | EP | claimed |
| WO-2001072765-A1 | ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING | ISIS PHARMACEUTICALS, INC. (US) | 2001-10-04 | — | — | WO | claimed |
| WO-2000004189-A1 | MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2000-01-27 | — | — | WO | claimed |